Radiation: Stress myocardial perfusion PET ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02714881 (ClinicalTrials.gov) | April 2016 | 14/3/2016 | Lipids, Inflammation, and CV Risk in RA | Lipids, Inflammation, and Cardiovascular Risk in Rheumatoid Arthritis | Rheumatoid Arthritis;Cardiovascular Disease | Drug: certolizumab;Radiation: Stress myocardial perfusion PET | Brigham and Women's Hospital | NULL | Active, not recruiting | 35 Years | 90 Years | All | 74 | N/A | United States |